In recent decades, several biomarkers have been investigated as predictors of breast cancer risk, development, prognosis and treatment efficacy.
Introduction
Efficacy in breast cancer early diagnosis, treatment and prevention is a big challenge considering that breast cancer is the most common diagnosed cancer in women worldwide. Biomarkers have a critical role both in monitoring cancer progression and assisting the identification of high-risk subjects. The general characteristics of a biomarker should include high reproducibility and detectability, easy collection from patients by minimally invasive techniques and high correlation with the disease with different expression in healthy versus affected subjects.
An ideal biomarker for monitoring cancer treatment should be strongly correlated with cancer growth and should be an index for drug efficacy. A good candidate biomarker for cancer prevention would be a marker directly correlated with risk and with molecular mechanisms of carcinogenesis in pre-cancerous tissues, should be differentially expressed in average versus high-risk populations and should predict response to chemopreventive agents. Several tumour markers have shown evidence of clinical usefulness and have been recommended for use in practice in breast cancer patients: CA 15-3, CA 27.29, carcinoembryonic antigen (CEA), oestrogen and progesterone receptors (ER, PR), human epidermal growth factor receptor 2 (HER-2), urokinase plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1) and certain multiparametre gene expression assays (Oncotype DX, MammaPrint, Rotterdam Signature) [1] .
In the last decade, much effort has been focused on discovering biomarkers that can be used to predict breast cancer risk. Among the established risk biomarkers, deleterious germline mutations in BRCA1/BRCA2/TP53 genes have been demonstrated as strong predictors of breast cancer development [2] and recent studies have also investigated the possible association between single nucleotide polymorphisms (SNPs) and breast cancer risk [3] [4] [5] . An association between levels of endogenous sex hormones with breast cancer risk have been shown in post-menopausal women [6, 7] , whereas other hormones and circulating biomarkers such as serum IGF-1, IGFBP-3 and also testosterone have been demonstrated to be associated with risk, especially in pre-menopausal women, although more recent data have also demonstrated relevance in post-menopause [8] [9] [10] [11] [12] .
Other potential biomarkers that have been investigated for an association with breast cancer include hormonal and nuclear receptors, membrane receptors and signal transduction factors, anti-inflammatory and antioxidant factors, apoptosis and angiogenesis factors, proliferation markers and antigens, epigenetic modulation factors, cellular inducible enzymes, cell cycle regulators, oncogenes and tumour suppressor genes [13, 14] .
In this review, we will discuss the main biomarkers which have been reported to have a role in breast cancer early development and progression.
Hormonal and nuclear receptors
Oestrogen and progesterone are essential hormones for breast growth, and their receptors (ER and PR) are established predictive factors for breast cancer treatment efficacy and disease outcome. ERs are transcription factors, which mediate the action of oestrogens, whereas the PR gene is regulated by oestrogen, and so the PR could be a marker of oestrogen action in breast cancer [15] .
Previous studies have shown that ER and PR levels are associated with a favourable breast cancer prognosis and are highly predictive of benefit from endocrine treatment in both the adjuvant and metastatic settings [16] [17] [18] . Two different isoforms for each receptor have been described: ERa· and ERb; PRA and PRB. Functional experiments have demonstrated that ERa and ERb have completely different roles in breast cancer: ERa acts as a tumour promoter, whereas ERb is a tumour suppressor. The presence of ERb in breast tumours is associated with better prognosis and longer disease-free survival [19] . ERa expression has been demonstrated to be increased in normal epithelium taken from a tumour-bearing breast [20] , and another study reported increased ERa expression in the tissue of women at high risk of developing breast cancer [21] . However, it is important to consider the relative amounts of ERa and ERb; as normal breast tissue becomes tumourigenic, the amount of ERa increases whereas the amount of ERb decreases [22] .
In normal breast, PRA and PRB are co-expressed at similar levels on luminal epithelial cells, suggesting that both proteins are required to mediate physiologically relevant progesterone signalling, and an imbalance in the native ratio of the two isoforms may lead to alterations in PR signalling [23, 24] . Previous studies have demonstrated that the ratio between PRA and PRB is altered during the breast carcinogenesis process [25, 26] .
Androgen receptors (AR) are expressed by the majority of human breast carcinomas, at a frequency comparable to or higher than that reported for ER and PR [27, 28] . AR shows a statistically significant association with important clinical and pathologic prognostic factors [29] , such as histopathological grade, tumour invasiveness and axillary lymph node involvement [30] [31] [32] [33] . Furthermore, some studies reported statistically significant associations between increased levels of testosterone and higher breast cancer risk in both pre-and post-menopausal healthy women [11, [34] [35] [36] , supporting a role for androgens and their receptors in breast carcinogenesis.
All these findings highlight the role of ER, PR and AR in promoting breast cancer and consequently their potential as drug targets in both preventive and therapeutic settings.
Other members of the steroid/thyroid hormone receptor super family include the nuclear retinoid receptors. Receptor selective retinoids inhibit the growth of both normal and cancerous human breast cells predominantly through induction of a G1 cell cycle block [37] . There are two classes of retinoid receptors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Both types of receptors are encoded by three distinct genes a, b and g. Their functional activities require dimerisation with a member of the nuclear non-steroidal receptor family, in particular RXRs dimerise with peroxisome proliferator-activated receptors (PPARs) and with the vitamin D receptor (VDR) [38] [39] [40] .
The RARs and RXRs are thought to mediate the effects of retinoids on cell growth, differentiation and apoptosis and, therefore, to have a role in mammary carcinogenesis suppression [41] [42] [43] . RARa expression has been demonstrated to be positively linked to proliferative activity and to ER expression [44] , whereas RARb may act as a tumour repressor gene, since its expression is progressively lost with increasing proliferative activity of the tumour [45] . Furthermore, an increasing RARa/RARb ratio may be a marker of progression from the pre-invasive to the invasive state in breast cancer [46] .
The PPARs are also members of the nuclear receptor super family, which includes steroid, retinoid and thyroid hormone receptors [47, 48] . Three isoforms of PPAR have been identified, a, d and g. PPARg has been found to be expressed in normal breast epithelium and breast cancers [49] . It heterodimerises with RXR and then binds to the peroxisome proliferator response elements in the promoter regions of targets genes, allowing for activation of gene transcription that is responsible for cell cycle modulation, cellular differentiation, decreased proliferation and inhibition of angiogenesis [50, 51] . [107] . Circulating IGF-I mainly binds to IGFBP-3, a protein that regulates the mitogenic actions of IGFs and inhibits their apoptotic effect and also has an IGF-independent inhibitory effect on cell growth [104]. Baxter and co-worker showed that IGFBP-3 production is potently induced by TGF-b and proposed a role for IGFBP-3 in mediating TGF-b inhibitory activity [108, 109] . IGFBP3 is also a ligand for the nuclear RXR-a receptor, which was shown to be necessary for IGFBP-3 induced apoptosis [110] . Results from a phase III breast cancer prevention trial with fenretinide, suggested that the reduction of IGF-I and IGFBP-3 levels may in part explain the cancer risk reduction observed in women <50 years of age [111] .
Inflammation and oxidation markers
Cyclooxygenase-2 (COX-2) is an important inflammatory mediator, responsible for the conversion of arachidonic acid into prostaglandins. In the last decade, several studies reported a correlation between COX-2 expression and breast cancer. Elevated COX-2 protein levels have been detected in approximately 40% of invasive breast cancers and COX-2 overexpression has been demonstrated to correlate with large tumour size, high grade, high proliferation, hormone receptor negative status and over-expression of HER-2 [112] [113] [114] [115] [116] [117] . The role of COX-2 in breast cancer pathogenesis suggested the COX-2 signalling as a target for breast cancer treatment and prevention. Some meta-analyses and case control studies reported a moderate reduction in risk of breast cancer, up to 24%, with non-steroidal anti-inflammatory drugs (NSAIDs) [118] [119] [120] . Pre-clinical studies suggested that celecoxib, which is a selective inhibitor of COX-2, is effective in both preventing and treating breast cancer in a dose-dependent manner [121, 122] . However, other trials have identified an increased cardiovascular risk associated with COX inhibitors, probably due to their selective depression of prostacyclin levels [123] . Sauter et al investigated the possible correlation between celecoxib administration and prostaglandin concentration in serum and nipple aspirate fluid (NAF), reporting a reduction of prostaglandin levels in NAF of post-menopausal high-risk women and a reduction in both NAF and plasma prostaglandin levels in women with newly diagnosed breast cancer [124] .
Further clinical trials are necessary to better understand the chemopreventive and treatment potential of celecoxib.
Matrix metalloproteinases (MMPs) are a family of proteases involved in the regulation of the cell microenvironment, matrix turnover, growth factor bioavailability and several aspects of immunity and inflammation. 
Apoptosis, cell cycle regulators and angiogenesis factors
The apoptosis-signalling pathway has an important role in cancer onset and progression. Many apoptotic proteins have been studied for an association with breast cancer pathogenesis. P53 has been shown to be a possible target of the immune system. Antibodies against p53 have been detected in different types of malignant disease, with the highest positivity rates observed for breast cancer [172] . There are studies reporting a significant correlation between presence of p53 antibodies and the detection of mutated p53 protein in tissue sections and higher serum levels of antibodies in breast cancer cases than in healthy subjects from the general population. Furthermore, in breast cancer patients the presence of p53 antibodies also indicated a shortened survival [173] [174] [175] .
Cyclin D1 is a key factor involved in the regulation of the G1-S phase transition during the cell cycle. Cyclin D1 over-expression has been observed in DCIS, suggesting a possible role in breast cancer development [176] [177] [178] . Previous studies have reported that in ER-positive breast cancer patients, cyclin D1 over-expression is associated with overall and relapse-free survival [179, 180] .
It has been shown that cyclin D1 can activate oestrogen receptor transcriptional activity in the absence of estradiol, and that this activity can be inhibited by 4-hydroxytamoxifen [181] . Furthermore, published in vitro data suggested that retinoids reduce cyclin D1 expression in human breast cancer cell lines [182, 183] . These data are of great interest, since fenretinide has shown to induce a significant risk reduction of second breast cancer in pre-menopausal women, suggesting a possible role as breast cancer chemopreventive agent in high-risk young women [184] .
Vascular endothelial growth factor (VEGF) is a key enhancer factor of angiogenesis, the process of new blood vessels formation, involved in cancer development and progression. 6 www.ecancermedicalscience.com
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Several studies have investigated the association between VEGF expression in cancer tissues and plasma with breast cancer. High levels of VEGF expression in breast cancer tissues have been associated with poor prognosis and decreased overall survival [185, 186] , and many authors have reported that circulating VEGF levels are increased among breast cancer women [187] [188] [189] . It has been suggested that VEGF expression may help predict the biologic aggressiveness of DCIS [190] . VEGF over-expression was found not only in DCIS, but also before remodelling of the fibroblastic stroma of pre-malignant breast lesions [191] . Furthermore, previous studies evaluating VEGF expression and angiogenesis in breast cancer patients, have reported that sex steroids regulate angiogenesis and increase VEGF expression [192] , whereas the agonist of the oestrogen receptor tamoxifen has been shown to decrease VEGF expression and angiogenesis [187, 189, 193] .
Proliferation markers and antigens
Several studies have been conducted to investigate the possible use of proliferation markers as breast cancer prognostic indicators. Various methods are available for the measurement of proliferation rates in tumours, including mitotic counts, estimation of the fraction of cells in S-phase of the cell cycle and proliferation-associated antigens [194] . A previous study reported that mitotic count was a stronger predictor of survival than tumour size and lymphatic or skin invasion [195] . However, one limitation of mitotic index as a measure of proliferation is that the duration of the mitotic phase of the cell cycle is variable and consequently the correlation of number of mitoses and proliferation rate is not necessarily linear [196] . The measurement of the fraction of cells in chromosomal DNA synthesis (the S-phase of cell cycle) is one of the standard methods of assessing proliferation, with various techniques that can detect DNA replication. Recently, alternative methods of assessing proliferation that are based on the detection of nuclear antigens by immunohistochemistry have been investigated. Ki67, a protein expressed in the nucleus during the cell cycle, is actually used as measure of proliferation [194] . It has been demonstrated that Ki67 correlates significantly with estimates of the mitotic count index and the measurement of the fraction of cells in S-phase [197, 198] . Several studies reported an association between Ki67 and disease-free and overall survival, with an increased risk of recurrence in tumours with a high Ki67 [199] [200] [201] . Several authors measured Ki67 in tamoxifen-treated breast cancer patients, all reporting a decrease in Ki67 [202] [203] [204] . Ki67 has been validated as a surrogate endpoint biomarker reflecting the superiority of anastrozole versus tamoxifen in early stage breast cancer, with a greater reduction in Ki67 being achieved with anastrozole [205] . In recent studies, Ki67 was measured either in random periareolar fine needle aspiration and in ductal lavage samples from women at high risk of developing breast cancer, and it was reported a significant association between Ki67 expression and atypia and cell yield, indicating Ki67 as a surrogate biomarker in early-phase chemoprevention trials [206, 207] .
Proliferating cell nuclear antigen (PCNA), a nuclear protein involved in DNA repair processes, has been investigated, but appear to correlate poorly with Ki67 and mitotic count, suggesting a more limited use in assessing proliferation [208] .
Conclusions
The biomarkers that have been discussed in this review are involved at different stages of the breast carcinogenesis multistep process. Each of the described biomarkers may be a target for drug treatment or prevention. Notwithstanding, we should take into account that the absolute benefit of a treatment varies greatly between individuals. Biomarkers may also be helpful for identification of high-risk subjects who will benefit from a given treatment. However, the currently available data do not support the implementation of a cancer risk model based on biomarkers evaluation. Further studies and prospective clinical randomised trials are necessary to better define whether and which biomarkers could be used in clinical practice for better treatment selection and patient follow-up. 
